Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | KIF11 | P52732 | 5/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29369556 | 1.00 | HTT (1.00) | HTTTHRBKIF11CTSVCTSL | |
| SCHEMBL8898607 | 1.00 | HTT (1.00) | HTTTHRBKIF11CTSVCTSL | |
| SCHEMBL8898611 | 1.00 | HTT (1.00) | HTTTHRBKIF11CTSVCTSL | |
| SCHEMBL8898736 | 0.99 | HTT (0.98) | HTTTHRBKIF11CTSVCTSL | |
| Hydrochloric Acid SCHEMBL31741907 | 0.99 | HTT (0.98) | HTTTHRBKIF11CTSVCTSL | |
| Hydrochloric Acid SCHEMBL1271897 | 0.99 | HTT (0.98) | HTTTHRBKIF11CTSVCTSL | |
| Hydrochloric Acid SCHEMBL1271899 | 0.99 | HTT (0.98) | HTTTHRBKIF11CTSVCTSL | |
| Hydrochloric Acid SCHEMBL1061360 | 0.99 | HTT (0.98) | HTTTHRBKIF11CTSVCTSL | |
| SCHEMBL8898703 | 0.87 | THRB (0.77) | HTTTHRBKIF11CTSVCTSL | |
| SCHEMBL8900565 | 0.87 | THRB (0.77) | HTTTHRBKIF11CTSVCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0812840-A1 | NOVEL QUINUCLIDINE DERIVATIVES HAVING TRICYCLIC FUSED HETERO RING | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-12-17 | — | — | EP | claimed |
| EP-3013371-A1 | RETT SYNDROME AND TREATMENTS THEREFORE | Rett Syndrome Research Trust (US) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014210389-A1 | RETT SYNDROME AND TREATMENTS THEREFORE | RETT SYNDROME RESEARCH TRUST (US) | 2014-12-31 | — | — | WO | disclosed |
| US-20140286945-A1 | ENZYME INHIBITOR FOR CANCER TREATMENT | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140286945-A1 | ENZYME INHIBITOR FOR CANCER TREATMENT | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2014-09-25 | — | — | US | disclosed |
| US-20090209510-A1 | Novel Method of Treating Hyperlipidemia | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090209510-A1 | Novel Method of Treating Hyperlipidemia | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090118255-A1 | Crp Lowering Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090118255-A1 | Crp Lowering Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090082333-A1 | REMEDY FOR XANTHOMA | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1889632-A1 | REMEDY FOR XANTHOMA | National University Corp. Kobe University (JP) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006129859-A2 | COMBINATIONS OF A SQUALENE SYNTHASE INHIBITOR AND A HMG-COA REDUCTASE INHIBITOR FOR TREATING HYPERLIPIDEMIA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-12-07 | — | — | WO | disclosed |
| EP-0812840-A1 | NOVEL QUINUCLIDINE DERIVATIVES HAVING TRICYCLIC FUSED HETERO RING | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082333-A1 | REMEDY FOR XANTHOMA | FDFT1, LSS, SQLE | HTT 4085/4885THRB 3582/4885KIF11 3659/4885 |
| US-20090118255-A1 | Crp Lowering Agent | SPR, RBP1, HMGCR | HTT 4387/4885THRB 1644/4885KIF11 4866/4885 |
| US-20090209510-A1 | Novel Method of Treating Hyperlipidemia | HMGCR, LIPC, LIPA | HTT 3546/4885THRB 2252/4885KIF11 4063/4885 |
| US-20140286945-A1 | ENZYME INHIBITOR FOR CANCER TREATMENT | LCAT, CES1, NCEH1 | HTT 4841/4885THRB 3885/4885KIF11 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.